The effects of dihydrotestosterone on the expression of p185(erbB-2) and c-erbB-2 mRNA in the prostatic cell line LNCaP

Journal of Steroid Biochemistry and Molecular Biology

Volumn 59, Issue 5-6, 1996, Pages 441-447

  Myers, R B ^a   Oelschlager, D K ^a   Hockett, R D ^a   Rogers, M D ^a   Conway Myers, B A ^b   Grizzle, William E ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA;

ARTICLE; CELL CULTURE; CELL GROWTH; CELL LINE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PROSTATE; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

DIHYDROTESTOSTERONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RNA, MESSENGER; THYMIDINE; TRITIUM; TUMOR CELLS, CULTURED;

EID: 0030477926     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00143-4     Document Type: Article

References (38)

1. 1. Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., Saito T. and Toyshima K.: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature (Lond.) 319 (1986) 230-234.
2. 2. Muller W. J., Sinn E., Pattengale P. K. and Leder P.: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54 (1988) 105-115.
3. 3. Sikes R. A. and Chung L. W. K.: Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene. Cancer Res. 52 (1992) 3174-3181.
4. 4. Lemoine N. R., Staddon S., Dickson C., Barnes D. M. and Gullick W. J.: Absence of activating transmembrane mutations in the c-erbB-2 protooncogene in human breast cancer. Oncogene 5 (1990) 237-239.
5. 5. Slamon D. J., Goddphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. G., Stuart S. G., Udove J., Ulrich A. and Press M. F.: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244 (1989) 707-712.
6. 6. Venter D. J., Tuzi N. L., Kumar S. and Gullick W. J.: Overexpression of the c-erbB-2 oncoprotein in human breast carcinoma: immunohistologic assessment correlates with gene amplification. Lancet 2 (1987) 69-72.
7. 7. Berger M. S., Locher G. W., Saurer S., Gullick W. J., Waterfield M. D., Groner B. and Hynes N. E.: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with node status and nuclear grading. Cancer Res. 48 (1988) 1238-1243.
8. 8. Tal M., Wetzler M., Josefberg Z., Deutch A., Gutman M., Assaf D., Kris R., Shiloh Y., Givol D. and Schlessinger J.: Sporadic amplification of the HER2/enu proto-oncogene in adenocarcinomas of various tissues. Cancer Res. 48 (1988) 1517-1520.
9. 9. Semba K., Kamata N., Toyshima K. and Yamamoto T.: A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in human salivary gland adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 6497-6501.
10. 10. Slamon D. J., Clark G. M., Wong S. G., Levin W. G., Ulrich A. and McGuire W. L.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182.
11. 11. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J. T., Dodge R., Clarke-Pearson P., Marks S., McKenzie S., Yiu S. and Blast R. C.: Overexpression of HER2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50 (1990) 4087-4091.
12. 12. McCann A., Dervan P. A., Johnston P. A., Gullick W. J. and Carney D. N.: c-erbB-2 oncoprotein expression in primary human tumors. Cancer 65 (1990) 65-88.
13. 13. Mellon K., Thompson S., Charton R. G., Marsh C., Robinson M., Lane D. P., Harris A. L., Wilson-Horne C. H. and Neal D. E.: p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J. Urol. 147 (1992) 496-499.
14. 14. Kuhn E. J., Kurnot R. A., Sesterhenn I. A., Chang E. H. and Moul J. W.: Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic adenocarcinoma. J. Urol. 150 (1993) 1427-1433.
15. 15. Ware J. L., Maygarden S. J., Koontz W. W. and Strom S. C.: Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum. Pathol. 22 (1991) 254-258.
16. 16. Sadasivan R., Morgan R., Jennings S., Austenfeld M., Van Veldhuizen P., Stephens R. and Noble M.: Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer. J. Urol. 150 (1993) 126-131.
17. neu) in prostate tumors: an immunohistochemical study. Prostate 23 (1993) 329-336.
18. erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl. Cancer Inst. 86 (1994) 1140-1145.
19. 19. Wright G. L., Grob M., Huang C. L., Troyer J, Adam B.-L., Cazares L. and Schellhammer P. F.: Comparison of HER2-neu in prostate and breast carcinomas. Proc. Am. Ass. Cancer Res. 36 (1995) 644A.
20. 20. Myers R. B., Srivastava S., Oelschlager D. K. and Grizzle W. E.: Serum levels of erbB-2 protein in patients with prostatic adenocarcinoma. Proceedings of the American Association of Cancer Research (1996) 645A.
21. 21. Sarkar F. H., Grignon D. J., Sakr W. A., Tabaczka P. and Crissman J. D.: Overexpression of erbB-2 gene in the prostate of African-American (AA) and Caucasian (C) men. Mod. Pathol. 9 (1996) 82A.
22. 22. Schuurmans A. L. G., Bolt J., Voorhorst M. M., Blankenstein R. A. and Mulder E.: Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids. Int. J. Cancer 42 (1988) 917-922.
23. 23. Schuurmans A. L. G., Bolt J. and Mulder E.: Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate 12 (1988) 55-63.
24. 24. Ravenna L., Lubrano C., DiSilverio F., Vacca A., Felli M. P., Maroder M., D'Eramo G., Sciarra F., Frati L. and Gulino A.: Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP. Prostate 26 (1995) 290-298.
25. 25. Laemmli U. K.: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685.
26. 26. Hockett R. D. Jr, Janowski K. M. and Bucy R. P.: Simultaneous quantitation of multiple cytokine mRNAs by RT-PCR, utilizing plate based EIA methodology. J. Immun. Meth. 187 (1995) 273-285.
27. 27. Hockett R. D. Jr, Rogers M. D. and Srivastava S.: Quantitative, competative RT-PCR analysis of biomarkers in the study of neoplasia. Meth. Molec. Biol. (1996) in press.
28. 28. Horoszewica J. S., Leong S. S., Kawinski E., Karr J. P., Rosenthal H., Ming Chu T., Mirand E. A. and Murphy G. P.: LNCaP model of human prostatic carcinoma. Cancer Res. 43 (1983) 1809-1818.
29. 29. Langeler E. G., VanUffelen C. J., Blankenstein M. A., Van Steenbrugge C. J. and Mulder E.: Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate 23 (1993) 213-223.
30. 30. Zhau H. E., Wan D. S., Zhou Z., Miller G. J. and Von Eschenbach A. C.: Expression of c-erbB-2 proto-oncogene in human prostatic cancer tissues and cell lines. Molec. Carcin. 5 (1992) 320-327.
31. 31. Dati C., Antoniotii S., Taverna D., Perroteau I. and DeBortoli M.: Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5 (1990) 1001-1006.
32. 32. Read L. D., Keith D., Slamon D. J. and Katzenellenbogen B. S.: Hormonal modulation of HER-2/neu proto-oncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res. 50 (1990) 3947-3951.
33. 33. DeBartoli M., Dati C., Antoniotti S., Maggiora P. and Sapei M. L.: Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells. J. Steroid Biochem. Molec. Biol. 43 (1992) 21-25.
34. 34. Russell K. S. and Hung M. C.: Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res. 52 (1992) 6624-6629.
35. 35. Veltri R. W., Partin A. W., Epstein J. E., Marley G. M., Miller G. M., Singer D. S., Patton K. P., Criley S. R. and Coffey D. S.: Quantitative nuclear morphometry, markovian texture descriptors and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2-NEU immunohistochemistry for prediction of prostate cancer progression. J. Cell. Biochem. 19 (Suppl. (1994) 249.
36. 36. Iglehart J. D., Kraus M. H., Langton B. C., Huper G., Kerns B. J. and Marks J. R.: Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res. 50 (1990) 6701-6707.
37. 37. Dubik D., Dembinski T. C. and Shiu R. P. C.: Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res. 47 (1987) 6517-6521.
38. 38. Van der Burg B., van Selm-Mitenburg A. J. P., de Laat S. W. van Zoelen E. J.: Direct effects of estrogen on c-fos and c-myc proto-oncogene expression and cellular proliferation in human breast cancer cells. Molec. Cell. Endocr. 64 (1989) 223-230.